tiprankstipranks
Astellas Pharma Inc (MX:4503N)
:4503N
Mexico Market
4503N
Astellas Pharma
RESEARCH TOOLSreports

Astellas Pharma (4503N) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

4503N Analyst Ratings

Hold
8Ratings
Hold
3 Buy
4 Hold
1 Sell
Based on 8 analysts giving stock ratings to
Astellas
Pharma
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

4503N Stock 12 Month Forecast

Average Price Target

$254.18
▲(0.24% Upside)
Based on 8 Wall Street analysts offering 12 month price targets for Astellas Pharma in the last 3 months. The average price target is $254.18 with a high forecast of $320.06 and a low forecast of $181.37. The average price target represents a 0.24% change from the last price of $253.57.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"180":"$180","321":"$321","215.25":"$215.3","250.5":"$250.5","285.75":"$285.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":320.0592,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$320.06</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":254.18034799999998,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$254.18</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":181.36688,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$181.37</span>\n  </div></div>","useHTML":true}}],"tickPositions":[180,215.25,250.5,285.75,321],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,253.57,258.68455384615385,263.7991076923077,268.91366153846155,274.02821538461535,279.1427692307692,284.25732307692306,289.3718769230769,294.48643076923076,299.6009846153846,304.7155384615385,309.83009230769227,314.9446461538461,{"y":320.0592,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,253.57,253.61694984615383,253.6638996923077,253.71084953846153,253.75779938461537,253.80474923076923,253.85169907692307,253.8986489230769,253.94559876923074,253.9925486153846,254.03949846153844,254.08644830769228,254.13339815384614,{"y":254.18034799999998,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,253.57,248.01591384615384,242.46182769230768,236.90774153846155,231.3536553846154,225.79956923076924,220.24548307692308,214.69139692307692,209.13731076923077,203.5832246153846,198.02913846153848,192.47505230769232,186.92096615384617,{"y":181.36688,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":199.299,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":199.299,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":199.299,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":204.11,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":204.11,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":225,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":225,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":225,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":281.91,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":281.91,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":281.91,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":253.57,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":253.57,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$320.06Average Price Target$254.18Lowest Price Target$181.37
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
SBI Securities Analyst forecast on MX:4503N
Unknown Analyst
SBI Securities
Not Ranked
SBI Securities
$241.11
Hold
-4.91%
Downside
Reiterated
07/29/26
Astellas Pharma (ALPMF) Receives a Hold from SBI Securities
Goldman Sachs Analyst forecast on MX:4503N
Unknown Analyst
Goldman Sachs
Not Ranked
Goldman Sachs
$314.72→$320.06
Buy
26.22%
Upside
Reiterated
07/17/26
Astellas Pharma (ALPMF) Gets a Buy from Goldman Sachs
UBS Analyst forecast on MX:4503N
Unknown Analyst
UBS
Not Ranked
UBS
$256.05→$245.38
Hold
-3.23%
Downside
Reiterated
07/15/26
Astellas Pharma (ALPMF) Receives a Hold from UBS
Daiwa Analyst forecast on MX:4503N
Unknown Analyst
Daiwa
Not Ranked
Daiwa
$181.37
Sell
-28.47%
Downside
Reiterated
07/14/26
Daiwa Remains a Sell on Astellas Pharma (ALPMF)
Bernstein Analyst forecast on MX:4503N
Miki Sogi
Bernstein
Bernstein
$234.71
Hold
-7.44%
Downside
Reiterated
07/07/26
Bernstein Sticks to Its Hold Rating for Astellas Pharma (ALPMF)
J.P. Morgan Analyst forecast on MX:4503N
Unknown Analyst
J.P. Morgan
Not Ranked
J.P. Morgan
$245.38
Hold
-3.23%
Downside
Reiterated
06/29/26
J.P. Morgan Sticks to Their Hold Rating for Astellas Pharma (ALPMF)
Bank of America Securities Analyst forecast on MX:4503N
Unknown Analyst
Bank of America Securities
Not Ranked
Bank of America Securities
$288.05
Buy
13.60%
Upside
Reiterated
06/05/26
Astellas Pharma (ALPMF) Receives a Buy from Bank of America Securities
Macquarie Analyst forecast on MX:4503N
Unknown Analyst
Macquarie
Not Ranked
Macquarie
$298.72→$277.38
Buy
9.39%
Upside
Reiterated
05/28/26
Astellas Pharma (ALPMF) Gets a Buy from Macquarie
Citi Analyst forecast on MX:4503N
Hidemaru Yamaguchi
Citi
Citi
$266.72→$256.05
Hold
0.98%
Upside
Reiterated
05/01/26
Astellas Pharma (ALPMF) Gets a Hold from Citi
Jefferies Analyst forecast on MX:4503N
Stephen Barker
Jefferies
Jefferies
$298.72
Buy
17.81%
Upside
Reiterated
03/24/26
Jefferies Keeps Their Buy Rating on Astellas Pharma (ALPMF)
Mizuho Securities Analyst forecast on MX:4503N
Unknown Analyst
Mizuho Securities
Not Ranked
Mizuho Securities
$266.72
Hold
5.18%
Upside
Reiterated
03/19/26
Astellas Pharma (ALPMF) Receives a Hold from Mizuho Securities
Nomura Analyst forecast on MX:4503N
Unknown Analyst
Nomura
Not Ranked
Nomura
$256.05→$266.72
Hold
5.18%
Upside
Downgraded
02/19/26
Nomura downgrades Astellas Pharma (ALPMF) to a Hold
SMBC Nikko Analyst forecast on MX:4503N
Unknown Analyst
SMBC Nikko
Not Ranked
SMBC Nikko
$181.37→$213.37
Hold
-15.85%
Downside
Reiterated
02/16/26
SMBC Nikko Sticks to Their Hold Rating for Astellas Pharma (ALPMF)
Morgan Stanley Analyst forecast on MX:4503N
Unknown Analyst
Morgan Stanley
Not Ranked
Morgan Stanley
$208.04→$218.71
Hold
-13.75%
Downside
Reiterated
02/05/26
Astellas Pharma (ALPMF) Gets a Hold from Morgan Stanley
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
SBI Securities Analyst forecast on MX:4503N
Unknown Analyst
SBI Securities
Not Ranked
SBI Securities
$241.11
Hold
-4.91%
Downside
Reiterated
07/29/26
Astellas Pharma (ALPMF) Receives a Hold from SBI Securities
Goldman Sachs Analyst forecast on MX:4503N
Unknown Analyst
Goldman Sachs
Not Ranked
Goldman Sachs
$314.72→$320.06
Buy
26.22%
Upside
Reiterated
07/17/26
Astellas Pharma (ALPMF) Gets a Buy from Goldman Sachs
UBS Analyst forecast on MX:4503N
Unknown Analyst
UBS
Not Ranked
UBS
$256.05→$245.38
Hold
-3.23%
Downside
Reiterated
07/15/26
Astellas Pharma (ALPMF) Receives a Hold from UBS
Daiwa Analyst forecast on MX:4503N
Unknown Analyst
Daiwa
Not Ranked
Daiwa
$181.37
Sell
-28.47%
Downside
Reiterated
07/14/26
Daiwa Remains a Sell on Astellas Pharma (ALPMF)
Bernstein Analyst forecast on MX:4503N
Miki Sogi
Bernstein
Bernstein
$234.71
Hold
-7.44%
Downside
Reiterated
07/07/26
Bernstein Sticks to Its Hold Rating for Astellas Pharma (ALPMF)
J.P. Morgan Analyst forecast on MX:4503N
Unknown Analyst
J.P. Morgan
Not Ranked
J.P. Morgan
$245.38
Hold
-3.23%
Downside
Reiterated
06/29/26
J.P. Morgan Sticks to Their Hold Rating for Astellas Pharma (ALPMF)
Bank of America Securities Analyst forecast on MX:4503N
Unknown Analyst
Bank of America Securities
Not Ranked
Bank of America Securities
$288.05
Buy
13.60%
Upside
Reiterated
06/05/26
Astellas Pharma (ALPMF) Receives a Buy from Bank of America Securities
Macquarie Analyst forecast on MX:4503N
Unknown Analyst
Macquarie
Not Ranked
Macquarie
$298.72→$277.38
Buy
9.39%
Upside
Reiterated
05/28/26
Astellas Pharma (ALPMF) Gets a Buy from Macquarie
Citi Analyst forecast on MX:4503N
Hidemaru Yamaguchi
Citi
Citi
$266.72→$256.05
Hold
0.98%
Upside
Reiterated
05/01/26
Astellas Pharma (ALPMF) Gets a Hold from Citi
Jefferies Analyst forecast on MX:4503N
Stephen Barker
Jefferies
Jefferies
$298.72
Buy
17.81%
Upside
Reiterated
03/24/26
Jefferies Keeps Their Buy Rating on Astellas Pharma (ALPMF)
Mizuho Securities Analyst forecast on MX:4503N
Unknown Analyst
Mizuho Securities
Not Ranked
Mizuho Securities
$266.72
Hold
5.18%
Upside
Reiterated
03/19/26
Astellas Pharma (ALPMF) Receives a Hold from Mizuho Securities
Nomura Analyst forecast on MX:4503N
Unknown Analyst
Nomura
Not Ranked
Nomura
$256.05→$266.72
Hold
5.18%
Upside
Downgraded
02/19/26
Nomura downgrades Astellas Pharma (ALPMF) to a Hold
SMBC Nikko Analyst forecast on MX:4503N
Unknown Analyst
SMBC Nikko
Not Ranked
SMBC Nikko
$181.37→$213.37
Hold
-15.85%
Downside
Reiterated
02/16/26
SMBC Nikko Sticks to Their Hold Rating for Astellas Pharma (ALPMF)
Morgan Stanley Analyst forecast on MX:4503N
Unknown Analyst
Morgan Stanley
Not Ranked
Morgan Stanley
$208.04→$218.71
Hold
-13.75%
Downside
Reiterated
02/05/26
Astellas Pharma (ALPMF) Gets a Hold from Morgan Stanley
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
ZURAZura Bio
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Astellas Pharma

3 Months
xAi Drug Manufacturers - GeneralTipRanks - xAI
Success Rate
1/2 ratings generated profit
50%
Average Return
+13.45%
Copying xAi Drug Manufacturers - General's trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +13.45% per trade.
1 Year
xAi Drug Manufacturers - GeneralTipRanks - xAI
Success Rate
1/2 ratings generated profit
50%
Average Return
+12.75%
Copying xAi Drug Manufacturers - General's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +12.75% per trade.
2 Years
xAi Drug Manufacturers - GeneralTipRanks - xAI
Success Rate
1/2 ratings generated profit
50%
Average Return
+12.75%
Copying xAi Drug Manufacturers - General's trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +12.75% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

4503N Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
0
0
0
0
0
Buy
4
5
5
4
3
Hold
11
9
7
6
8
Sell
1
0
0
0
1
Strong Sell
0
0
0
0
0
total
16
14
12
10
12
In the current month, 4503N has received 3 Buy Ratings, 8 Hold Ratings, and 1 Sell Ratings. 4503N average Analyst price target in the past 3 months is 254.18.
Each month's total comprises the sum of three months' worth of ratings.

4503N Financial Forecast

4503N Earnings Forecast

Next quarter’s earnings estimate for 4503N is $5.96 with a range of $4.85 to $7.36. The previous quarter’s EPS was $2.68. 4503N beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 58.33% of the time in the same period. In the last calendar year 4503N has Performed in-line its overall industry.
Next quarter’s earnings estimate for 4503N is $5.96 with a range of $4.85 to $7.36. The previous quarter’s EPS was $2.68. 4503N beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 58.33% of the time in the same period. In the last calendar year 4503N has Performed in-line its overall industry.

4503N Sales Forecast

Next quarter’s sales forecast for 4503N is $61.65B with a range of $58.40B to $64.25B. The previous quarter’s sales results were $59.27B. 4503N beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 66.67% of the time in the same period. In the last calendar year 4503N has Performed in-line its overall industry.
Next quarter’s sales forecast for 4503N is $61.65B with a range of $58.40B to $64.25B. The previous quarter’s sales results were $59.27B. 4503N beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 66.67% of the time in the same period. In the last calendar year 4503N has Performed in-line its overall industry.

4503N Stock Forecast FAQ

What is MX:4503N’s average 12-month price target, according to analysts?
Based on analyst ratings, Astellas Pharma Inc’s 12-month average price target is 254.18.
    What is MX:4503N’s upside potential, based on the analysts’ average price target?
    Astellas Pharma Inc has 0.24% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Astellas Pharma Inc a Buy, Sell or Hold?
          Astellas Pharma Inc has a consensus rating of Hold, which is based on 3 buy ratings, 4 hold ratings and 1 sell ratings.
            What is Astellas Pharma Inc’s share price target?
            The average share price target for Astellas Pharma Inc is 254.18. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $320.06 ,and the lowest forecast is $181.37. The average share price target represents 0.24% Increase from the current price of $253.57.
              What do analysts say about Astellas Pharma Inc?
              Astellas Pharma Inc’s analyst rating consensus is a Hold. This is based on the ratings of 8 Wall Streets Analysts.
                How can I buy shares of Astellas Pharma Inc?
                To buy shares of MX:4503N, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.